GraniteShares 2x Long COIN Daily ETF vs Definium Therapeutics Inc. Common Shares — how do they compare? GraniteShares 2x Long COIN Daily ETF trades at $5.3 (market cap $510.01M), while Definium Therapeutics Inc. Common Shares trades at $37.05 (market cap $4.59B). The key difference: Definium Therapeutics Inc. Common Shares is far larger — about 9× GraniteShares 2x Long COIN Daily ETF's market cap, and Definium Therapeutics Inc. Common Shares is trading nearer its 52-week high, GraniteShares 2x Long COIN Daily ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold GraniteShares 2x Long COIN Daily ETF for 15 Days and Definium Therapeutics Inc. Common Shares for 0 Days on average.
| CONL | DFTX | |
|---|---|---|
Market Cap | $510.01M | $4.59B |
Volume | 21,041,836 | 2,103,937 |
Sector | Leveraged / Inverse | Health |
52-Week High | $48.58 | $48.45 |
52-Week Low | $3.93 | $10.68 |
Typical Hold Time | 15 Days | 0 Days |
Enterprise Value | — | $3.55B |
Signals from Pluang's Aura AI — not financial advice
CONL, a leveraged ETF tracking COIN, trades at $5.26, up 0.57% today. Technical indicators show mixed signals with a bearish overall trend but bullish oscillators including oversold RSI readings. The stock faces resistance at $5 and support at $4. Recent news highlights volatility with significant price gaps and volume spikes.
Outlook remains highly volatile given the leveraged structure and dependence on COIN performance. Investment opportunities exist for short-term traders capitalizing on momentum swings, but risks include amplified losses, regulatory uncertainty, and crypto market sensitivity. Long-term investors should approach with caution.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
CONL is a leveraged ETF that seeks to provide two times (2x) the daily performance of Coinbase Global (COIN) stock. It is designed for investors seeking magnified short-term exposure to the price movements of Coinbase.
Read more on CONL →Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →